8-K: Quantum-Si Secures $100M At-The-Market Equity Offering

Quantum-Si Incorporated has entered into a sales agreement with Leerink Partners LLC to potentially sell up to $100 million of Class A common stock through an at-the-market offering.

Summary

• Quantum-Si Incorporated entered into a Sales Agreement with Leerink Partners LLC on September 26, 2025.
• The agreement allows Quantum-Si to offer and sell from time to time, at its sole discretion, up to an aggregate of $100,000,000 of its Class A common stock.
• Leerink Partners will act as sales agent or principal for these sales, which may be conducted as "at-the-market" offerings.
• The company has no obligation to sell any shares and may at any time suspend offers or terminate the Sales Agreement.
• Quantum-Si will pay Leerink Partners commissions of up to 3.0% of the gross offering proceeds received per share sold.
• The company has also agreed to reimburse Leerink Partners up to an aggregate of $75,000 for initial outside legal expenses, plus certain ongoing outside legal expenses.
• The issuance and sale of shares are subject to the effectiveness of the company's shelf registration statement on Form S-3, filed with the SEC on September 26, 2025.

Sentiment

Score: 6

Explanation: The filing indicates a proactive step to secure future funding, which is generally positive for financial flexibility. However, the potential for shareholder dilution and the costs associated with the offering introduce a moderate negative aspect. It's a neutral-to-slightly positive move for long-term stability, but not an immediate catalyst for significant positive sentiment.

Positives

• Provides Quantum-Si with flexible access to up to $100 million in capital, enhancing financial liquidity and strategic optionality.
• Allows the company to raise funds opportunistically based on market conditions, potentially minimizing the impact of a single large offering.
• The "at-the-market" structure offers flexibility in the timing and pricing of share sales, adapting to market demand.

Negatives

• Potential for shareholder dilution if the company sells a significant number of shares under the agreement.
• A commission rate of up to 3.0% of gross proceeds will reduce the net funds received by the company.
• Reimbursement of Leerink Partners' legal expenses up to $75,000, plus ongoing expenses, adds to the cost of capital.
• No assurance that the registration statement will become effective or remain effective, which could limit the company's ability to raise funds.

Risks

• **Market Conditions:** The ability to sell shares and the price at which they can be sold are dependent on prevailing market conditions and investor demand, which are subject to volatility.
• **Shareholder Dilution:** Future sales of Class A common stock under the Sales Agreement could dilute the ownership interest and per-share value of existing shareholders.
• **Registration Statement Effectiveness:** The offering is contingent on the effectiveness and continued effectiveness of the company's shelf registration statement on Form S-3, which is not guaranteed.
• **Uncertainty of Proceeds:** The company may choose not to offer or sell any shares, or market conditions may prevent significant sales, meaning the full $100 million may not be realized.

Future Outlook

Quantum-Si may offer and sell shares of its Class A common stock from time to time, at its sole discretion, through Leerink Partners, subject to market conditions and the effectiveness of its shelf registration statement. The company makes no assurances regarding the effectiveness of the registration statement or its continued effectiveness, and may choose not to sell any shares.

Management Comments

• The Company may offer and sell from time to time at its sole discretion up to an aggregate of $100,000,000 of shares of the Company's Class A common stock.
• The Company may ultimately choose not to offer or sell any Shares under the Sales Agreement.
• The Company has no obligation to sell any of the Shares and may at any time suspend offers under the Sales Agreement or terminate the Sales Agreement.

Industry Context

At-the-market (ATM) offerings are a common and flexible capital-raising tool for publicly traded companies, particularly those in growth-oriented sectors like biotechnology or life sciences, which often require significant capital for research, development, and commercialization. This method allows companies to tap into equity markets gradually, minimizing immediate dilution compared to a large secondary offering, and to raise funds as needed without the pressure of a single large transaction. Many companies utilize such facilities to maintain financial flexibility and strengthen their balance sheets.

Comparison to Industry Standards

• NA

Stakeholder Impact

• **Shareholders:** Potential for dilution of existing shareholdings if the company sells a significant number of shares under the agreement.
• **Leerink Partners LLC:** Will benefit from commissions of up to 3.0% on any shares sold, as well as reimbursement for legal expenses.
• **Company (Quantum-Si):** Gains increased financial flexibility and access to capital for future operations and growth initiatives.

Next Steps

• The company may, at its discretion, instruct Leerink Partners to sell shares of Class A common stock under the Sales Agreement.
• The effectiveness of the shelf registration statement on Form S-3 is required before any sales can commence.

Key Dates

Recommendation

This filing primarily concerns a financing mechanism rather than operational performance or strategic breakthroughs. While securing access to capital is a prudent move for a growth company, the potential for future share dilution could exert downward pressure on the stock price. Investors should 'hold' to observe the actual utilization of this facility and its impact on the company's financial health and share structure, rather than making an immediate buy or sell decision based solely on the establishment of an ATM program.

Keywords

Quantum-Si, QSI, Equity Offering, At-The-Market, ATM, Capital Raise, Common Stock, Leerink Partners, SEC Filing, Form 8-K, Dilution, Financing